Implications of the Incidental Finding of a MYCN Amplified Adrenal Tumor: A Case Report and Update of a Pediatric Disease Diagnosed in Adults

Overview

Journal Case Rep Oncol Med

Publisher Wiley

Specialty Oncology

Date 2014 Jan 8

PMID 24396620

Citations 1

Authors

Anna Koumarianou

Panagiota Oikonomopoulou

Margarita Baka

Dimitrios Vlachodimitropoulos

Stylianos Argentos

Theodoros Piperos

Maria-Ioanna Christodoulou

Kakoulis Theodoulou

Theodoros Mariolis-Sapsakos

Affiliations

Soon will be listed here.

Abstract

MYCN is a well-known oncogene overexpressed in different human malignancies including neuroblastoma, rhabdomyosarcoma, medulloblastoma, astrocytoma, Wilms' tumor, and small cell lung cancer. While neuroblastoma is one of the most common childhood malignancies, in adults it is extremely rare and its treatment is based on pediatric protocols that take into consideration stage and genotypic features, such as MYCN amplification. Although neuroblastoma therapy has evolved, identification of early stage patients who need chemotherapy continues to pose a therapeutic challenge. The emerging prognostic role of MYCN phenotype of this disease is currently under investigation as it may redefine MYCN amplified subgroups. We describe an unusual case of adult neuroblastoma with MYCN amplification diagnosed incidentally and discuss possible therapeutic dilemmas.

Citing Articles

Adult neuroblastoma in the retroperitoneum: A case report.

Wu X, Dai Y, Sun G, Wang L, Han L, Qu M Medicine (Baltimore). 2018; 97(51):e13750.

PMID: 30572519 PMC: 6320202. DOI: 10.1097/MD.0000000000013750.

References

Nakagawa A, Matsuoka K, Okita H, Iwafuchi H, Hori H, Kumagai M . Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology. Pediatr Dev Pathol. 2011; 14(2):87-92. DOI: 10.2350/08-12-0579.1. View

Alvarado C, London W, Look A, Brodeur G, Altmiller D, Thorner P . Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study. J Pediatr Hematol Oncol. 2000; 22(3):197-205. DOI: 10.1097/00043426-200005000-00003. View

Valentijn L, Koster J, Haneveld F, Aissa R, van Sluis P, Broekmans M . Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc Natl Acad Sci U S A. 2012; 109(47):19190-5. PMC: 3511149. DOI: 10.1073/pnas.1208215109. View

Ambros P, Ambros I, Brodeur G, Haber M, Khan J, Nakagawara A . International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer. 2009; 100(9):1471-82. PMC: 2694415. DOI: 10.1038/sj.bjc.6605014. View

Brodeur G, Pritchard J, Berthold F, Carlsen N, Castel V, Castelberry R . Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993; 11(8):1466-77. DOI: 10.1200/JCO.1993.11.8.1466. View

Suganuma R, Wang L, Sano H, Naranjo A, London W, Seeger R . Peripheral neuroblastic tumors with genotype-phenotype discordance: a report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee. Pediatr Blood Cancer. 2012; 60(3):363-70. PMC: 3397468. DOI: 10.1002/pbc.24238. View

Mueller S, Matthay K . Neuroblastoma: biology and staging. Curr Oncol Rep. 2009; 11(6):431-8. DOI: 10.1007/s11912-009-0059-6. View

Cohn S, Look A, JOSHI V, Holbrook T, Salwen H, Chagnovich D . Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study. Cancer Res. 1995; 55(4):721-6. View

Bagatell R, Beck-Popovic M, London W, Zhang Y, Pearson A, Matthay K . Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. J Clin Oncol. 2008; 27(3):365-70. PMC: 2651034. DOI: 10.1200/JCO.2008.17.9184. View

10.

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

11.

Brodeur G, Seeger R, Schwab M, Varmus H, Bishop J . Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984; 224(4653):1121-4. DOI: 10.1126/science.6719137. View

12.

Buechner J, Einvik C . N-myc and noncoding RNAs in neuroblastoma. Mol Cancer Res. 2012; 10(10):1243-53. DOI: 10.1158/1541-7786.MCR-12-0244. View

13.

Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T . The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer Cell. 2012; 22(1):117-30. PMC: 3417812. DOI: 10.1016/j.ccr.2012.06.001. View

14.

Bown N . Neuroblastoma tumour genetics: clinical and biological aspects. J Clin Pathol. 2001; 54(12):897-910. PMC: 1731335. DOI: 10.1136/jcp.54.12.897. View

15.

Shimada H, Umehara S, Monobe Y, Hachitanda Y, Nakagawa A, Goto S . International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer. 2001; 92(9):2451-61. DOI: 10.1002/1097-0142(20011101)92:9<2451::aid-cncr1595>3.0.co;2-s. View

16.

FRANKS L, Bollen A, Seeger R, Stram D, Matthay K . Neuroblastoma in adults and adolescents: an indolent course with poor survival. Cancer. 1997; 79(10):2028-35. DOI: 10.1002/(sici)1097-0142(19970515)79:10<2028::aid-cncr26>3.0.co;2-v. View

17.

Hasegawa T, Hirose T, Ayala A, Ito S, Tomaru U, Matsuno Y . Adult neuroblastoma of the retroperitoneum and abdomen: clinicopathologic distinction from primitive neuroectodermal tumor. Am J Surg Pathol. 2001; 25(7):918-24. DOI: 10.1097/00000478-200107000-00010. View

18.

Young Jr W . Clinical practice. The incidentally discovered adrenal mass. N Engl J Med. 2007; 356(6):601-10. DOI: 10.1056/NEJMcp065470. View

19.

Attiyeh E, London W, Mosse Y, Wang Q, Winter C, Khazi D . Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005; 353(21):2243-53. DOI: 10.1056/NEJMoa052399. View

20.

Tonini G, Nakagawara A, Berthold F . Towards a turning point of neuroblastoma therapy. Cancer Lett. 2012; 326(2):128-34. DOI: 10.1016/j.canlet.2012.08.017. View